WO2017203395A1 - Crystalline forms of tenofovir alafenamide hemi fumarate - Google Patents
Crystalline forms of tenofovir alafenamide hemi fumarate Download PDFInfo
- Publication number
- WO2017203395A1 WO2017203395A1 PCT/IB2017/052896 IB2017052896W WO2017203395A1 WO 2017203395 A1 WO2017203395 A1 WO 2017203395A1 IB 2017052896 W IB2017052896 W IB 2017052896W WO 2017203395 A1 WO2017203395 A1 WO 2017203395A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tenofovir alafenamide
- preparation
- acid
- tenofovir
- solvent
- Prior art date
Links
- SVUJNSGGPUCLQZ-FQQAACOVSA-N tenofovir alafenamide fumarate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 41
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 34
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 42
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 claims description 41
- 229960004946 tenofovir alafenamide Drugs 0.000 claims description 39
- 239000002904 solvent Substances 0.000 claims description 29
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 22
- 239000012535 impurity Substances 0.000 claims description 20
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 20
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000001530 fumaric acid Substances 0.000 claims description 12
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 12
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 239000002178 crystalline material Substances 0.000 claims description 9
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 9
- -1 phenyl hydrogen ((R)-l-(6-amino-9H-purin-9-yl) propan-2-yloxy) methylphosphonate Chemical compound 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 150000002825 nitriles Chemical class 0.000 claims description 8
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 6
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 230000002140 halogenating effect Effects 0.000 claims description 5
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 4
- QDQVXVRZVCTVHE-YFKPBYRVSA-N propan-2-yl (2s)-2-aminopropanoate Chemical compound CC(C)OC(=O)[C@H](C)N QDQVXVRZVCTVHE-YFKPBYRVSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- GTSOBGIMTNKIPJ-UHFFFAOYSA-N OP(Cl)=O Chemical compound OP(Cl)=O GTSOBGIMTNKIPJ-UHFFFAOYSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 abstract description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract description 4
- 229960003767 alanine Drugs 0.000 abstract description 4
- MIILDBHEJQLACD-KPORQTCDSA-N propan-2-yl (2s)-2-[[(2,3,4,5,6-pentafluorophenoxy)-phenoxyphosphoryl]amino]propanoate Chemical compound FC=1C(F)=C(F)C(F)=C(F)C=1OP(=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1 MIILDBHEJQLACD-KPORQTCDSA-N 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 47
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229960004592 isopropanol Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229960004556 tenofovir Drugs 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- PRIZZBIPYUFPTN-SNVBAGLBSA-N C[C@H](Cc1nc(N)c2[nH]cnc2n1)OCP(O)(=O)Oc1ccccc1 Chemical compound C[C@H](Cc1nc(N)c2[nH]cnc2n1)OCP(O)(=O)Oc1ccccc1 PRIZZBIPYUFPTN-SNVBAGLBSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- IACQCQDWSIQSRP-ZCFIWIBFSA-N [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-[hydroxy(phosphonooxy)phosphoryl]oxyphosphinic acid Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=NC2=C1N IACQCQDWSIQSRP-ZCFIWIBFSA-N 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 239000001099 ammonium carbonate Substances 0.000 description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229960005335 propanol Drugs 0.000 description 4
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000000798 anti-retroviral effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- MEJAFWXKUKMUIR-FHPNUNMMSA-N (e)-but-2-enedioic acid;propan-2-yl (2s)-2-[[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 MEJAFWXKUKMUIR-FHPNUNMMSA-N 0.000 description 2
- 229940044613 1-propanol Drugs 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- VERWQPYQDXWOGT-LVJNJWHOSA-N 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VERWQPYQDXWOGT-LVJNJWHOSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000016903 DNA Polymerase gamma Human genes 0.000 description 2
- 108010014080 DNA Polymerase gamma Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 2
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 229940093097 genvoya Drugs 0.000 description 2
- 150000008282 halocarbons Chemical class 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229940124525 integrase strand transfer inhibitor Drugs 0.000 description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 2
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 2
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 2
- 239000002370 magnesium bicarbonate Substances 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- YAQKNCSWDMGPOY-JEDNCBNOSA-N propan-2-yl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.CC(C)OC(=O)[C@H](C)N YAQKNCSWDMGPOY-JEDNCBNOSA-N 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 2
- 229940007718 zinc hydroxide Drugs 0.000 description 2
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 2
- FOTRUJUPLHRVNU-QNBGGDODSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid;hydrate Chemical compound O.C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 FOTRUJUPLHRVNU-QNBGGDODSA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- CMIBUZBMZCBCAT-HOTGVXAUSA-N (2s,3s)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HOTGVXAUSA-N 0.000 description 1
- YONLFQNRGZXBBF-KBPBESRZSA-N (2s,3s)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@H](C(=O)O)[C@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-KBPBESRZSA-N 0.000 description 1
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 1
- LSPHULWDVZXLIL-LDWIPMOCSA-N (?)-Camphoric acid Chemical compound CC1(C)[C@@H](C(O)=O)CC[C@@]1(C)C(O)=O LSPHULWDVZXLIL-LDWIPMOCSA-N 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- 0 **(Oc1ccccc1)=O Chemical compound **(Oc1ccccc1)=O 0.000 description 1
- SGOIRFVFHAKUTI-UHFFFAOYSA-N 1-(6-aminopurin-9-yl)propan-2-yloxymethylphosphonic acid Chemical compound N1=CN=C2N(CC(C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-UHFFFAOYSA-N 0.000 description 1
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical class C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N 5-oxo-D-proline Chemical compound OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102000005572 Cathepsin A Human genes 0.000 description 1
- 108010059081 Cathepsin A Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- BVMWIXWOIGJRGE-UHFFFAOYSA-N NP(O)=O Chemical compound NP(O)=O BVMWIXWOIGJRGE-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- ITAMCOCNZJPJDF-LLVKDONJSA-N [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphinic acid Chemical compound O([C@@H](CN1C2=NC=NC(N)=C2N=C1)C)CP(O)(=O)OC1=CC=CC=C1 ITAMCOCNZJPJDF-LLVKDONJSA-N 0.000 description 1
- MIOPJNTWMNEORI-MHPPCMCBSA-N [(4r)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-MHPPCMCBSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 description 1
- 229960002402 cobicistat Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 description 1
- 229960003586 elvitegravir Drugs 0.000 description 1
- 229940120915 emtricitabine and tenofovir alafenamide Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- PZQSQRCNMZGWFT-QXMHVHEDSA-N propan-2-yl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(C)C PZQSQRCNMZGWFT-QXMHVHEDSA-N 0.000 description 1
- QDQVXVRZVCTVHE-UHFFFAOYSA-N propan-2-yl 2-aminopropanoate Chemical compound CC(C)OC(=O)C(C)N QDQVXVRZVCTVHE-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to novel crystalline forms of L-alanine, N-[(S)-[[( ⁇ R)-2-
- Tenofovir Alafenamide hemi fumarate Plasma exposure to Tenofovir Alafenamide hemi fumarate allows for permeation into cells and then Tenofovir Alafenamide hemi fumarate is intracellularly converted to Tenofovir through hydrolysis by cathepsin A. Tenofovir is subsequently phosphorylated by cellular kinases to the active metabolite Tenofovir diphosphate. Tenofovir diphosphate inhibits HIV replication through incorporation into viral DNA by the HIV reverse transcriptase, which results in DNA chain- termination.
- Tenofovir specifically shows activity towards human immunodeficiency virus and hepatitis B virus.
- Cell culture studies have shown that both Emtricitabine and Tenofovir can be fully phosphorylated when combined in cells.
- Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase ⁇ and there is no evidence of toxicity to mitochondria in cell culture.
- Tenofovir Alafenamide hemi fumarate was approved by USFDA in 2015 and is marketed under the brand name GENVOYA®, is a four-drug combination of Elvitegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), Cobicistat, a CYP3A inhibitor, and Emtricitabine and Tenofovir Alafenamide (TAF), both HIVl nucleoside analog reverse transcriptase inhibitors (NRTIs) and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 R A less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of GENVOYA.
- INSTI HIV-1 integrase strand transfer inhibitor
- Tenofovir has activity that is specific to human immunodeficiency virus and hepatitis B virus. Cell culture studies have shown that both Emtricitabine and Tenofovir can be fully phosphorylated when combined in cells. Tenofovirdiphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase ⁇ and there is no evidence of toxicity to mitochondria in cell culture.
- Tenofovir Alafenamide hemi fumarate is chemically known as L-alanine, N-[(S)-[[(1R)- 2-(6-amino-9H-purin-9-yl)-lmethylethoxy]methyl]phenoxy phosphinyl]-,l-methylethyl ester, (2E)-2-butenedioate).
- Tenofovir Alafenamide hemi fumarate is a white to off-white or tan powder with a solubility of 4.7 mg per mL in water at 20°C. It has a molecular formula of C2 3 H 3 i0 7 N 6 P and a molecular weight of 534.5.
- WO2015/040640 discloses a process for the preparation of Tenofovir Alafenamide comprises
- WO2015/079455 discloses a process for racemization of (R,R,S)-diastereomer or a mixture having (R,S,S) & (R,R,S)-diastereomer of Tenofovir Alafenamide, said method comprising treating the (R,R,S)-diastereomer or the mixture having (R,S,S) & (R,R,S)- diastereomer with a suitable base in a suitable organic solvent.
- WO 2015/107451 discloses a process for the purification of Tenofovir Alafenamide, comprising the steps of
- acid is selected from chiral acid such as of (S)-(+)-mandelic acid, (R)-(-)-mandelic Acid, (lS)-(+)-10- camphor sulfonic acid, (lR)-(-)-10-camphor sulfonic acid, (D)-(-)-tartaric acid, (L)-(+)-Tartaric acid, (-)-di-p-toluoyl-L-tartaric acid, (+)-di-p-toluoyl-D-tartaric acid, (L)-(-)-malic acid, (D)-(+)-malic acid, (+)-dibenzoyl-D-tartaric acid, (-)- dibenzoyl-L-tartaric acid, (1R, 3S)-(+)-camphoric acid, (I S, 3R)-(-)-camphoric acid, L-pyroglutamic acid, and D- pyl
- the present invention provides an improved process for the preparation of substantially pure novel crystalline forms of Tenofovir Alafenamide hemifumarate, wherein substantially pure material having a purity of greater than 99.5% by HPLC and meeting the quality of ICH guidelines.
- Tenofovir Alafenamide hemifumarate crystalline material obtained by the process of the present invention is chemically stable and has been found with good dissolution properties.
- the main objective of the invention relates to new stable crystalline polymorphic forms of Tenofovir Alafenamide hemifumarate.
- Yet another objective of the invention relates to process for the preparation of new stable crystalline polymorphic forms of Tenofovir Alafenamide hemifumarate.
- Yet another objective of the invention relates to a process for the preparation of highly pure Tenofovir Alafenamide hemifumarate, which is stable and thermodynamically stable.
- the present invention relates to Tenofovir Alafenamide hemifumarate characterized by X-ray powder diffraction pattern comprising characteristic 2Q° peaks selected from 5.2, 7.3, 10.3, 1 1.1 , 18.5, 19.4, 21.1, 22.2, 26.5 ⁇ 0.2°2 ⁇ .
- the present invention further relates to a process for the preparation of Tenofovir Alafenamide hemifumarate comprising the steps of:
- the present invention relates to a process for the preparation of Tenofovir Alafenamide or its pharmaceutically acceptable salt thereof, comprising the steps of:
- Fig. 1 is an example of X-ray powder diffraction ("XRPD") pattern of Tenofovir Alafenamide hemi fumarate Form -STA obtained according to the process of the present invention.
- XRPD X-ray powder diffraction
- Fig. 2 is an example of example of DSC endotherm of Tenofovir Alafenamide hemi fumarate Form -STA obtained according the present invention.
- aspects of the present invention relates to the new stable polymorphic forms of Tenofovir Alafenamide hemi fumarate designated as Form-STA.
- Tenofovir Alafenamide hemi fumarate crystalline Form-STA characterized by X-ray powder diffraction pattern comprising characteristic 2 ⁇ ° peaks selected from 5.2, 7.3, 10.3, 11.1, 18.5, 19.4, 21.1, 22.2, 26.5 ⁇ 0.2°2 ⁇ .
- Tenofovir Alafenamide hemi fumarate crystalline Form-STA was further characterized by X-ray powder diffraction pattern comprising characteristic 29° peaks selected from 10.9, 12.2, 12.8, 14.2, 14.8, 15.3, 15.7, 16.5, 17.6, 18.8, 21.7, 24.4, 26.9 ⁇ 0.2°2 ⁇ .
- the present invention provides Tenofovir
- the present invention provides Tenofovir Alafenamide hemi fumarate contains fumaric acid content ranging from 10.40-11.4 % w/w.
- the present invention relates to a process for the preparation of Tenofovir Alafenamide hemi fumarate comprising, dissolving Tenofovir Alafenamide in a solvent selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol, amylalcohol; nitrile solvents such as acetonitrile or propionitrile or mixtures thereof; at a temperature ranging between 0°C to 65°C. Adding fumaric acid, wherein fumaric acid was added in the range of 0.4-0.6 moles to obtain desired Tenofovir Alafenamide hemi fumarate. The obtained crystalline material was recovered and dried the crystalline material at 60-65°C to yield highly pure Tenofovir Alafenamide hemi fumarate.
- the present invention further relates to a process for the preparation of Tenofovir
- Alafenamide or its pharmaceutically acceptable salts such as mono fumarate, hemi fumarate comprising adding (R)-((-l-(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonic acid in a solvent selected from alcohols, such as C2-C6 alcohols like ethanol, 1 -propanol, 2- propanol (isopropyl alcohol), 1 -butanol, 2-butanol, t-butyl alcohol; or nitriles, such as acetonitrile or propionitrile; amides such as ⁇ , ⁇ -dimethylformamide, N,N- dimethylacetamide, N-methyl-2-pyrrolidone; sulfoxides such as dimethylsulfoxide; halogenated hydrocarbons such as dichloromethane; aromatic hydrocarbons such as toluene, xylene; esters such as ethyl acetate, n-propyl a
- reaction mass phenol was added.
- base which was selected from organic base such as triethylamine, methylamine, pyridine, imidazole, benzimidazole; or inorganic base selected from carbonates such as sodium carbonate, potassium carbonate, calcium carbonate, ammonium carbonate; hydroxides such as sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, barium hydroxide, magnesium hydroxide, lithium hydroxide, zinc hydroxide; bicarbonates such as sodium bicarbonate, potassium bicarbonate, ammonium bicarbonate, calcium bicarbonate, magnesium bicarbonate.
- the obtained reaction mass was heated to 80-120°C and maintained stirring for 4 hours to 8 hours.
- the solvent was removed at atmospheric pressure under nitrogen at 80°C; the reaction mixture was washed with toluene twice at atmospheric pressure under nitrogen at 80°C, cooled to 25°C, diluted with dichloromethane. The reaction mass as such was used for next stage.
- the prior art process disclosed in prior art involves the stirring for longer hours (92 hours) for chiral enhancement.
- the present inventors surprisingly found that the reaction will complete with in the 3 hours.
- the chiral purity is around 65-80%.
- the present inventors are able to prepare the Tenofovir Alafenamide having a purity of greater than 99.5 % and free of diastereomeric impurities using the process as described in the present invention.
- the prior art process involves the use of high volumes (5 volumes) of halogenating agent for completion of the reaction, which leads to the formation of highly chlorinated byproducts/impurities.
- the present inventors surprisingly found that the reaction will complete with the use of 2.5 equivalents of halogenating agent for completion of the reaction, which yields in a highly pure Tenofovir Alafenamide free of highly halogenated impurities.
- a mixture of L-alanine isopropyl ester hydrochloride was dissolved in a solvent selected from alcohols, such as C2-C6 alcohols like ethanol, 1-propanol, 2- propanol (isopropyl alcohol), 1-butanol, 2-butanol, t-butyl alcohol; or nitriles, such as acetonitrile or propionitrile; amides such as ⁇ , ⁇ -dimethylformamide, N,N- dimethylacetamide, N-methyl-2-pyrrolidone; sulfoxides such as dimethylsulfoxide; halogenated hydrocarbons such as dichloromethane; aromatic hydrocarbons such as toluene, xylene; esters such as ethyl acetate, n-propyl acetate, n-butyl acetate, isopropyl acetate, isobutyl acetate, t-butyl acetate;
- alcohols such as
- reaction mass base selected from organic base such as triethylamine, methylamine, pyridine, imidazole, benzimidazole; or inorganic base selected from carbonates such as sodium carbonate, potassium carbonate, calcium carbonate, ammonium carbonate; hydroxides such as sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, barium hydroxide, magnesium hydroxide, lithium hydroxide, zinc hydroxide; bicarbonates such as sodium bicarbonate, potassium bicarbonate, ammonium bicarbonate, calcium bicarbonate, magnesium bicarbonate was added slowly and maintained reaction mass at room temperature for 5 h. The obtained reaction mass was filtered to remove solids and filtrate was cooled to -30°C to -10°C.
- organic base such as triethylamine, methylamine, pyridine, imidazole, benzimidazole
- inorganic base selected from carbonates such as sodium carbonate, potassium carbonate, calcium carbonate, ammonium carbonate
- hydroxides such
- the obtained racemic Tenofovir Alafenamide having a diastereomeric purity of around 65- 80% was dissolved in a solvent, wherein solvent is selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol; ether such as diethyl ether, diisopropyl ether, methyl t-butyl ether, tetrahydrofuran, 1 ,4-dioxane, 2-methoxyethanol, anisole or nitrile solvents such as acetonitrile or propionitrile or mixtures thereof.
- solvent is selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol; ether such as diethyl ether, diisopropyl ether, methyl t-butyl ether, tetrahydrofuran, 1 ,4-dioxane, 2-
- reaction mass Heated the reaction mass to a temperature ranging between 60-85°C and maintained the reaction mass under stirring for a period of 30 min to 1 hour to get clear solution. Cooled the reaction mass to 45-50°C and charge solvent if necessary, wherein solvent selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol; ether such as diethyl ether, diisopropyl ether, methyl t-butyl ether, tetrahydrofuran, 1 ,4-dioxane, 2-methoxyethanol, anisole or nitrile solvents such as acetonitrile or propionitrile or mixtures thereof.
- solvent selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol; ether such as diethyl ether, diisopropyl ether, methyl t-butyl ether,
- reaction mass Cooled the reaction mass to room temperature and stirred the reaction mass for 12 hours to 14 hours at same temperature Further, cooled the reaction mass to 0-5°C and stirred the mass for 4-5 h. Filtered the reaction mass and washed withabove used solvent. The wet compound was taken into flask and charged Isopropyl alcohol. Heated the reaction mass to 70-75°C and maintained for 30 min to 1 hour to get clear solution.
- reaction mass Cooled the reaction mass to 45-50°C and charged solvent selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol; ether such as diethyl ether, diisopropyl ether, methyl t-butyl ether, tetrahydrofuran, 1 .4- dioxane, 2-methoxyethanol, anisole or nitrile solvents such as acetonitrile or propionitrile or mixtures thereof. Cooled the reaction mass to room temperature and stirred for 3-4 h at same temperature. Filtered the reaction mass and washed with same solvent and dried the solid under vacuum at 50°C for 6 hours to 8 hours to yield pure Tenofovir Alafenamide.
- solvent selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol; ether such as diethyl ether, diisopropyl
- the above disclosed process may be performed by using seeding process, Tenofovir Alafenamide obtained in the above stage having chiral purity of above 99% may be used for performing seeding.
- the present inventors surprisingly performed this process by using a single solvent.
- Tenofovir Alafenamide hemi fumarate obtained by the present invention is having an enantiomerically purity of greater than 99.5% and substantially free of diastereomeric impurities.
- Tenofovir Alafenamide was dissolved in amyl alcohol and methanol and 0.4 moles to 0.6 moles of Fumaric acid was added and stirred for 30 min at room temperature.
- the above mass was passed through micron filter and washed with methanol.
- the filtrate mass was distilled out below 3 volumes with respect to batch size under reduced pressure at below 50°C.
- the reaction mass was heated to 60-65 °C, maintained for 30 min and cooled to room temperature. Cyclohexane was added in to reaction mass and cooled to 0-5°C and maintained for 5 h.
- the product was isolated by filtration, washed with Cyclohexane and dried the compound at 60-65 °C for 10-12 h under reduced pressure to yield Tenofovir Alafenamide Fumaric acid salt.
- Tenofovir Alafenamide Fumaric acid salt in another embodiment of the present invention relates to substantially pure Tenofovir Alafenamide hemi fumarate having enantiomeric purity of greater than 99.5% and total impurities A to J and diastereomeric impurity collectively less than 0.5% by HPLC.
- Impurit -J Diastereomeric Impurity The word “Substantially pure” means Tenofovir Alafenamide hemi fumarate having a purity of greater than 99.5 % by HPLC and less than 0.05 % of diastereomeric impurities or the impurity levels within the limits as per the ICH guidelines.
- the substantially pure Tenofovir Alafenamide hemi fumarate is having a purity of greater than 99.5 % and meeting the ICH guidelines.
- the substantially pure Tenofovir Alafenamide hemi fumarate is having a purity of greater than 99.6 % and meeting the ICH guidelines. In one embodiment the substantially pure Tenofovir Alafenamide hemi fumarate is having a purity of greater than 99.7 % and meeting the ICH guidelines.
- the substantially pure Tenofovir Alafenamide hemi fumarate is having a purity of greater than 99.8 % and meeting the ICH guidelines.
- the substantially pure Tenofovir Alafenamide hemi fumarate is having a purity of greater than 99.9 % and meeting the ICH guidelines.
- the process related impurities that appear in the impurity profile of the Tenofovir is having a purity of greater than 99.9 % and meeting the ICH guidelines.
- Alafenamide hemi fumarate may be substantially removed by the process of the present invention resulting in the formation of highly pure material.
- the process of the present invention is as summarized below:
- the Tenofovir Alafenamide or its hemi fumarate obtained by the processes of the present application may be formulated as solid compositions for oral administration in the form of capsules, tablets, pills, powders or granules.
- the active product is mixed with one or more pharmaceutically acceptable excipients.
- the drug substance can be formulated as liquid compositions for oral administration including solutions, suspensions, syrups, elixirs and emulsions, containing solvents or vehicles such as water, sorbitol, glycerine, propylene glycol or liquid paraffin.
- compositions for parenteral administration can be suspensions, emulsions or aqueous or non-aqueous sterile solutions.
- a solvent or vehicle propylene glycol, polyethylene glycol, vegetable oils, especially olive oil, and injectable organic esters, e.g. ethyl oleate, may be employed.
- These compositions can contain adjuvants, especially wetting, emulsifying and dispersing agents.
- the sterilization may be carried out in several ways, e.g. using a bacteriological filter, by incorporating sterilizing agents in the composition, by irradiation or by heating. They may be prepared in the form of sterile compositions, which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
- compositions comprising Tenofovir Alafenamide hemi fumarate obtained as per the present application process- include, but are but not limited to diluents such as starch, pregelatinized starch, lactose, powdered cellulose, microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, mannitol, sorbitol, sugar and the like; binders such as acacia, guar gum, tragacanth, gelatin, pre-gelatinized starch and the like; disintegrants such as starch, sodium starch glycolate, pregelatinized starch, Croscarmellose sodium, colloidal silicon dioxide and the like; lubricants such as stearic acid, magnesium stearate, zinc stearate and the like; glidants such as colloidal silicon dioxide and the like; solubility or wetting enhancers such as anionic or cationic or neutral surfactants, waxes and the like.
- diluents such as starch
- compositions derived from Tenofovir Alafenamide hemi fumarate of the present application may also comprise to include the pharmaceutically acceptable carrier used for the preparation of solid dispersion, wherever utilized in the desired dosage form preparation.
- Phenol (6.54 g, 0.069 mol), and 1 -methyl 2-pyrrolidinone (NMP) (30.0 mL) was charged in to reaction flask containing anhydrous ((-l-(6-amino-9H-purin-9-yl)propan-2- yloxy)methylphosphonic acid (10.0 g 0.034mol), The reaction mixture was heated to 85°C. and Triethylamine (TEA) (4.35 g, 0.043 mol) was added slowly.
- TEA Triethylamine
- the pH of the aqueous solution was adjusted to 2 to 3 with Conc.HCl.
- the crude solid was isolated by filtration and washed with methanol (8.7 mL).
- the wet cake was slurred in methanol (40.0 mL).
- Solids were isolated by filtration and washed with methanol (6.0 mL). The resulting solid was dried under reduced pressure to yield title compound.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to novel crystalline forms of L-alanine,N-[(S)-[[(lR)-2-(6- amino-9H-purin-9-yl)-1methylethoxy]methyl]phenoxyphosphinyl]-1-methylethyl ester, (2E)- 2-butenedioate or Tenofovir Alafenamide hemi fumarate(I). The present invention further relates to a process for the enantiomerically pure Tenofovir Alafenamide hemi fumarate having an enantiomeric purity of greater than 99.5%
Description
CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE HEMI FUMARATE
FIELD OF THE INVENTION
The present invention relates to novel crystalline forms of L-alanine, N-[(S)-[[(\R)-2-
(6-amino-9H-purin-9-yl)- 1 methylethoxy]methyl]phenoxyphosphinyl]-, 1 -methylethyl ester hemi fumarate or Tenofovir Alafenamide hemi fumarate of Formula (I).
BACKGROUND OF THE INVENTION
L-alanine, N-[(S)-[[(lR)-2-(6-amino-9H-purin-9-yl)-lmethylethoxy]methyl]phenoxy phosphinyl]-,l -methylethyl ester, (2E)-2-butenedioate (2: 1) or Tenofovir Alafenamide hemi fumarate ( Hemi fumarate). Tenofovir Alafenamide hemi fumarate is a phosphonoamidate prodrug of Tenofovir (2 'deoxy adenosine monophosphate analog). Plasma exposure to Tenofovir Alafenamide hemi fumarate allows for permeation into cells and then Tenofovir Alafenamide hemi fumarate is intracellularly converted to Tenofovir through hydrolysis by cathepsin A. Tenofovir is subsequently phosphorylated by cellular kinases to the active metabolite Tenofovir diphosphate. Tenofovir diphosphate inhibits HIV replication through incorporation into viral DNA by the HIV reverse transcriptase, which results in DNA chain- termination.
Tenofovir specifically shows activity towards human immunodeficiency virus and hepatitis B virus. Cell culture studies have shown that both Emtricitabine and Tenofovir can be fully phosphorylated when combined in cells. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase γ and there is no evidence of toxicity to mitochondria in cell culture. Tenofovir Alafenamide hemi fumarate was approved by USFDA in 2015 and is marketed under the brand name GENVOYA®, is a four-drug combination of Elvitegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), Cobicistat, a CYP3A inhibitor, and Emtricitabine and Tenofovir Alafenamide (TAF), both HIVl nucleoside analog reverse transcriptase inhibitors (NRTIs) and is indicated as a complete regimen for the treatment of
HIV-1 infection in adults and pediatric patients 12 years of age and older who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 R A less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of GENVOYA.
Tenofovir has activity that is specific to human immunodeficiency virus and hepatitis B virus. Cell culture studies have shown that both Emtricitabine and Tenofovir can be fully phosphorylated when combined in cells. Tenofovirdiphosphate is a weak inhibitor of mammalian DNA polymerases that include mitochondrial DNA polymerase γ and there is no evidence of toxicity to mitochondria in cell culture.
Tenofovir Alafenamide hemi fumarate is chemically known as L-alanine, N-[(S)-[[(1R)- 2-(6-amino-9H-purin-9-yl)-lmethylethoxy]methyl]phenoxy phosphinyl]-,l-methylethyl ester, (2E)-2-butenedioate). Tenofovir Alafenamide hemi fumarate is a white to off-white or tan powder with a solubility of 4.7 mg per mL in water at 20°C. It has a molecular formula of C23H3i07N6P and a molecular weight of 534.5.
Tenofovir Alafenamide mono fumarate is generically and specifically disclosed in US
7390791. US '791disclose a process for the preparation of Tenofovir Alafenamide mono fumarate starting from Tenofovir. The process is as demonstrated below:
US 8664386 discloses process for the preparation of Tenofovir Alafenamide comprises diastereomeric separation of 9-{(R)-2-[((R,S)-{[(S)-l-(isopropoxycarbonyl)ethyl] amino }phenoxyphosphinyl) methoxyjpropyl} adenine. The process is as demonstrated below:
US 8754065 (which were also issued as US8697675) disclose Tenofovir Alafenamide hemi fumarate. Mainly this patent discloses crystalline polymorphic form of Tenofovir Alafenamide hemi fumarate having an X-ray powder diffraction (XRPD) pattern comprises values at 6.9and 8.6±0.2°2theta. WO2014195724 discloses a process for preparing 9-[(R)-2-[[(R)-[[(S)-l-
(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine or 9-[(R)-2- [[(S)-[[(S)-l-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl] adenine reacting phenyl (R)- 1 -(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonochloridate with 2-amino propionic acid isopropyl ester in presence of chiral organic acid.
WO2015/040640 discloses a process for the preparation of Tenofovir Alafenamide comprises
(i) reacting PMPA with phenol in presence of a base and a condensing agent in a suitable organic solvent to obtain [(R)-2-(Phenylphosphonomethoxy) propyl] adenine (ii) reacting the [(R)-2-(Phenylphosphonomethoxy)propyl] adenine or a reactive derivative with L-alanine isopropyl ester in presence of a base to obtain Tenofovir Alafenamide.
WO2015/079455 discloses a process for racemization of (R,R,S)-diastereomer or a mixture having (R,S,S) & (R,R,S)-diastereomer of Tenofovir Alafenamide, said method comprising treating the (R,R,S)-diastereomer or the mixture having (R,S,S) & (R,R,S)- diastereomer with a suitable base in a suitable organic solvent..
WO 2015/107451 discloses a process for the purification of Tenofovir Alafenamide, comprising the steps of
(i) reacting racemic Tenofovir Alafenamide with an acid to produce an acid salt; and
(ii) desaltification of the acid salt to get Tenofovir Alafenamide.
wherein acid is selected from chiral acid such as of (S)-(+)-mandelic acid, (R)-(-)-mandelic Acid, (lS)-(+)-10- camphor sulfonic acid, (lR)-(-)-10-camphor sulfonic acid, (D)-(-)-tartaric acid, (L)-(+)-Tartaric acid, (-)-di-p-toluoyl-L-tartaric acid, (+)-di-p-toluoyl-D-tartaric acid, (L)-(-)-malic acid, (D)-(+)-malic acid, (+)-dibenzoyl-D-tartaric acid, (-)- dibenzoyl-L-tartaric acid, (1R, 3S)-(+)-camphoric acid, (I S, 3R)-(-)-camphoric acid, L-pyroglutamic acid, and D- pyroglutamic acid; or an achiral acid such as orotic acid, fumaric acid, oxalic acid, maleic acid, benzoic acid, p-toluenesulphonic acid, succinic acid, orthophosphoric acid, and malonic acid.
In view of the above it is pertinent to note that there exists an inherent need to develop stable crystalline form of Tenofovir Alafenamide hemifumarate having further improved physical and/or chemical properties besides high purity levels. Hence it was thought worthwhile by the inventors of the present application to explore novel process/crystallization process for the preparation of Tenofovir Alafenamide hemi fumarate, which may further improve the characteristics of drug Tenofovir Alafenamide hemifumarate and in developing the substantially pure stable crystalline forms of Tenofovir Alafenamide hemifumarate consistently obtainable and amenable to scale up.
As polymorphism has been given importance in the recent literatures owing to its relevance to the drugs having oral dosage forms due to its apparent relation to dose preparation/suitability in composition steps/ bioavailability and other pharmaceutical profiles, stable polymorphic form of a drug has often remained the clear choice in compositions due to various reasons of handling, mixing and further processing including bioavailability and stability.
Exploring new polymorphic form for developing a stable and pure form of Tenofovir Alafenamide hemifumarate, which are amenable to scale up for pharmaceutically active useful compounds in the preparation of Tenofovir Alafenamide hemifumarate may thus provide an opportunity to improve the drug performance characteristics of products such as purity and solubility. Hence, inventors of the present application report a new polymorphic form, which is a stable and substantially pure form of Tenofovir Alafenamide hemifumarate, which may be industrially amenable and usable for preparing the corresponding pharmaceutical compositions. The present invention provides an improved process for the preparation of substantially pure novel crystalline forms of Tenofovir Alafenamide hemifumarate, wherein substantially pure material having a purity of greater than 99.5% by HPLC and meeting the quality of ICH guidelines. Tenofovir Alafenamide hemifumarate crystalline material obtained by the process of the present invention is chemically stable and has been found with good dissolution properties.
In view of the above and to overcome the prior-art problems the present inventors had now developed a new polymorphic forms of Tenofovir Alafenamide hemifumarate, which are substantially pure, stable produced by using industrially friendly solvents, which does not include tedious work up and time lagging steps.
OBJECTIVE OF THE INVENTION
The main objective of the invention relates to new stable crystalline polymorphic forms of Tenofovir Alafenamide hemifumarate.
Yet another objective of the invention relates to process for the preparation of new stable crystalline polymorphic forms of Tenofovir Alafenamide hemifumarate.
Yet another objective of the invention relates to a process for the preparation of highly pure Tenofovir Alafenamide hemifumarate, which is stable and thermodynamically stable.
SUMMARY OF THE INVENTION
The present invention relates to Tenofovir Alafenamide hemifumarate characterized by X-ray powder diffraction pattern comprising characteristic 2Q° peaks selected from 5.2, 7.3, 10.3, 1 1.1 , 18.5, 19.4, 21.1, 22.2, 26.5±0.2°2Θ.
The present invention further relates to a process for the preparation of Tenofovir Alafenamide hemifumarate comprising the steps of:
a) dissolving Tenofovir Alafenamide in a solvent;
b) adding fumaric acid;
c) recover the crystalline material; and
d) drying the crystalline material between 60-65°C.
The present invention relates to a process for the preparation of Tenofovir Alafenamide or its pharmaceutically acceptable salt thereof, comprising the steps of:
comprising the steps of:
a) reacting [(R)-2-(Phenylphosphonomethoxy) propyl] adenine with halogenating agent to provide Phosphono chloridic acid, P-[[(lR)-2-(6-amino-9-H-purin-9-yl)-l- methylethoxy] methyl] -phenyl ester of Formula (IV);
(HI) (IV) b) reacting compound of Formula IV with L- Alanine Isopropyl Ester to provide racemic
Tenofovir Alafenamide(V);
c) reacting racemic Tenofovir Alafenamide(V) with a solvent to provide greater than 95% diasteromerically pure Tenofovir Alafenamide (I)
d) optionally treating with salt forming acid to obtain Tenofovir Alafenamide salt.
In yet another aspect of the present invention relates to substantially pure Tenofovir Alafenamide hemi fumarate having enantiomeric purity of greater than 99.5% and total impurities A to J and diastereomeric impurity (R, R, S) collectively less than 0.3% by Chiral HPLC.
Impurity-J Diastereomeric Impurity
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is an example of X-ray powder diffraction ("XRPD") pattern of Tenofovir Alafenamide hemi fumarate Form -STA obtained according to the process of the present invention.
Fig. 2 is an example of example of DSC endotherm of Tenofovir Alafenamide hemi fumarate Form -STA obtained according the present invention.
DETAILED DESCRIPTION OF THE INVENTION
Aspects of the present invention relates to the new stable polymorphic forms of Tenofovir Alafenamide hemi fumarate designated as Form-STA.
In one aspect of present invention, it relates to Tenofovir Alafenamide hemi fumarate crystalline Form-STA characterized by X-ray powder diffraction pattern comprising characteristic 2Θ° peaks selected from 5.2, 7.3, 10.3, 11.1, 18.5, 19.4, 21.1, 22.2, 26.5±0.2°2Θ.
Tenofovir Alafenamide hemi fumarate crystalline Form-STA was further characterized by X-ray powder diffraction pattern comprising characteristic 29° peaks selected from 10.9, 12.2, 12.8, 14.2, 14.8, 15.3, 15.7, 16.5, 17.6, 18.8, 21.7, 24.4, 26.9 ±0.2°2Θ.
In another aspect of present invention, the present invention provides Tenofovir
Alafenamide hemi fumarate crystalline Form-STA characterized by DSC isotherm comprising endothermic peak ranging between 109 to 1 14°C.
In another aspect of present invention, the present invention provides Tenofovir Alafenamide hemi fumarate contains fumaric acid content ranging from 10.40-11.4 % w/w.
Further aspect of the present invention relates to process for the preparation of Tenofovir Alafenamide hemi fumarate comprising the steps of:
a) dissolving Tenofovir Alafenamide in a solvent;
b) adding fumaric acid;
c) recover the crystalline material; and
d) drying the crystalline material between 60-65°C.
The present invention relates to a process for the preparation of Tenofovir Alafenamide hemi fumarate comprising, dissolving Tenofovir Alafenamide in a solvent selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol, amylalcohol; nitrile solvents such as acetonitrile or propionitrile or mixtures thereof; at a temperature ranging between 0°C to 65°C. Adding fumaric acid, wherein fumaric acid was added in the range of 0.4-0.6 moles to obtain desired Tenofovir Alafenamide hemi fumarate. The obtained crystalline material was recovered and dried the crystalline material at 60-65°C to yield highly pure Tenofovir Alafenamide hemi fumarate. The present invention further relates to a process for the preparation of Tenofovir
Alafenamide or its pharmaceutically acceptable salts such as mono fumarate, hemi fumarate comprising adding (R)-((-l-(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonic acid in a solvent selected from alcohols, such as C2-C6 alcohols like ethanol, 1 -propanol, 2- propanol (isopropyl alcohol), 1 -butanol, 2-butanol, t-butyl alcohol; or nitriles, such as acetonitrile or propionitrile; amides such as Ν,Ν-dimethylformamide, N,N- dimethylacetamide, N-methyl-2-pyrrolidone; sulfoxides such as dimethylsulfoxide; halogenated hydrocarbons such as dichloromethane; aromatic hydrocarbons such as toluene, xylene; esters such as ethyl acetate, n-propyl acetate, n-butyl acetate, isopropyl acetate, isobutyl acetate, t-butyl acetate; ethers such as diethyl ether, diisopropyl ether, methyl t-butyl ether, tetrahydrofuran, 1 ,4-dioxane, 2-methoxyethanol, anisole; ketones such as acetone, ethyl methyl ketone, diethyl ketone, methyl isobutyl ketone; organic solvents such as dimethyl formamide, n-hexane, n-heptane, cyclohexane, cycloheptane; hetero aromatic solvents such as pyridine, dimethyl amino pyridine; water or mixtures thereof. To the reaction mass phenol was added. The reaction mass was heated to 60-90°C and then base was added, which was selected from organic base such as triethylamine, methylamine, pyridine, imidazole, benzimidazole; or inorganic base selected from carbonates such as sodium carbonate, potassium carbonate, calcium carbonate, ammonium carbonate; hydroxides such as sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, barium hydroxide, magnesium hydroxide, lithium hydroxide, zinc hydroxide; bicarbonates such as sodium bicarbonate, potassium bicarbonate, ammonium bicarbonate, calcium bicarbonate, magnesium bicarbonate. The obtained reaction mass was heated to 80-120°C and maintained stirring for 4 hours to 8 hours. The reaction mass was cooled to 45°C, water was added and further cooled to room temperature. The reaction mass was filtered and washed with water. The obtained reaction mass was filtered through the Celite bed and
washed with dichloromethane twice. The crude solid was isolated by filtration and washed with methanol. The wet cake was slurred and washed with methanol. The resulting solid was dried under reduced pressure to yield Phenyl hydrogen((R)-l-(6-amino-9H-purin-9- yl)propan-2-yloxy)methylphosphonate
Phenyl hydrogen((R)- 1 -(6-amino-9H-purin-9-yl)propan-2-yloxy)methylphosphonate obtained above under halogenations using a halogenating agent selected from Iodine, Bromine, Chlorine, thionyl chloride, oxalyl chloride, Phosphorous tri-chloride, Phosphorous penta-chloride, Phosphorous oxy chloride; at a temperature ranging from 75°C to 80°c for 3 hrs. The solvent was removed at atmospheric pressure under nitrogen at 80°C; the reaction mixture was washed with toluene twice at atmospheric pressure under nitrogen at 80°C, cooled to 25°C, diluted with dichloromethane. The reaction mass as such was used for next stage.
The prior art process disclosed in prior art involves the stirring for longer hours (92 hours) for chiral enhancement. The present inventors surprisingly found that the reaction will complete with in the 3 hours. However, the chiral purity is around 65-80%. Even after preparing the Tenofovir Alafenamide with low diastereomeric purity, the present inventors are able to prepare the Tenofovir Alafenamide having a purity of greater than 99.5 % and free of diastereomeric impurities using the process as described in the present invention.
The prior art process involves the use of high volumes (5 volumes) of halogenating agent for completion of the reaction, which leads to the formation of highly chlorinated byproducts/impurities. The present inventors surprisingly found that the reaction will complete with the use of 2.5 equivalents of halogenating agent for completion of the reaction, which yields in a highly pure Tenofovir Alafenamide free of highly halogenated impurities.
In a second flask a mixture of L-alanine isopropyl ester hydrochloride was dissolved in a solvent selected from alcohols, such as C2-C6 alcohols like ethanol, 1-propanol, 2- propanol (isopropyl alcohol), 1-butanol, 2-butanol, t-butyl alcohol; or nitriles, such as acetonitrile or propionitrile; amides such as Ν,Ν-dimethylformamide, N,N- dimethylacetamide, N-methyl-2-pyrrolidone; sulfoxides such as dimethylsulfoxide; halogenated hydrocarbons such as dichloromethane; aromatic hydrocarbons such as toluene, xylene; esters such as ethyl acetate, n-propyl acetate, n-butyl acetate, isopropyl acetate, isobutyl acetate, t-butyl acetate; ethers such as diethyl ether, diisopropyl ether, methyl t-butyl
ether, tetrahydrofuran, 1 ,4-dioxane, 2-methoxyethanol, anisole; ketones such as acetone, ethyl methyl ketone, diethyl ketone, methyl isobutyl ketone; organic solvents such as dimethyl formamide, n-hexane, n-heptane, cyclohexane, cycloheptane; water; or any mixtures. To the reaction mass base selected from organic base such as triethylamine, methylamine, pyridine, imidazole, benzimidazole; or inorganic base selected from carbonates such as sodium carbonate, potassium carbonate, calcium carbonate, ammonium carbonate; hydroxides such as sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, barium hydroxide, magnesium hydroxide, lithium hydroxide, zinc hydroxide; bicarbonates such as sodium bicarbonate, potassium bicarbonate, ammonium bicarbonate, calcium bicarbonate, magnesium bicarbonate was added slowly and maintained reaction mass at room temperature for 5 h. The obtained reaction mass was filtered to remove solids and filtrate was cooled to -30°C to -10°C. To the reaction mass above obtained, acid chloride reaction mass was added slowly for a period of 10 to 15 min. The reaction mixture was stirred for 30 min to 1 hour at same temperature (-30°C to -10°C), raised to room temperature. The organic layer was washed with water, 10% sodium di hydrogen orthophosphate solution twice. Followed by treatment with 10% potassium bi carbonate solution and with water. The organic layer was concentrated and co-distilled with acetonitrile under reduced pressure to obtain 9-[(R)-2-[{(S)-[{(S)-l-(isopropoxycarbonyl) ethyl] amino] phenoxyPhosphinyl] methoxy] propyl] adenine (Racemic Tenofovir Alafenamide in the ratio of R,S,S:R,R.S=65-80:35-20).
The obtained racemic Tenofovir Alafenamide having a diastereomeric purity of around 65- 80% was dissolved in a solvent, wherein solvent is selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol; ether such as diethyl ether, diisopropyl ether, methyl t-butyl ether, tetrahydrofuran, 1 ,4-dioxane, 2-methoxyethanol, anisole or nitrile solvents such as acetonitrile or propionitrile or mixtures thereof. Heated the reaction mass to a temperature ranging between 60-85°C and maintained the reaction mass under stirring for a period of 30 min to 1 hour to get clear solution. Cooled the reaction mass to 45-50°C and charge solvent if necessary, wherein solvent selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol; ether such as diethyl ether, diisopropyl ether, methyl t-butyl ether, tetrahydrofuran, 1 ,4-dioxane, 2-methoxyethanol, anisole or nitrile solvents such as acetonitrile or propionitrile or mixtures thereof. Cooled the reaction mass to room temperature and stirred the reaction mass for 12 hours to 14 hours at same temperature Further, cooled the reaction mass to 0-5°C and stirred the mass for 4-5 h. Filtered the reaction
mass and washed withabove used solvent. The wet compound was taken into flask and charged Isopropyl alcohol. Heated the reaction mass to 70-75°C and maintained for 30 min to 1 hour to get clear solution. Cooled the reaction mass to 45-50°C and charged solvent selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol; ether such as diethyl ether, diisopropyl ether, methyl t-butyl ether, tetrahydrofuran, 1 .4- dioxane, 2-methoxyethanol, anisole or nitrile solvents such as acetonitrile or propionitrile or mixtures thereof. Cooled the reaction mass to room temperature and stirred for 3-4 h at same temperature. Filtered the reaction mass and washed with same solvent and dried the solid under vacuum at 50°C for 6 hours to 8 hours to yield pure Tenofovir Alafenamide.
The above disclosed process may be performed by using seeding process, Tenofovir Alafenamide obtained in the above stage having chiral purity of above 99% may be used for performing seeding. The present inventors surprisingly performed this process by using a single solvent.
However, the prior art process involves the use of saltification technique, which is difficult and involves tedious work up to remove the unwanted impurities/by products and salts.
Even after the diastereomeric purity of Tenofovir Alafenamide is around 70%.The present inventors successfully removed the diastereomeric impurity by following the process as disclosed in the present invention to yield highly pure Tenofovir Alafenamide hemi fumarate free of diastereomeric impurities. Tenofovir Alafenamide hemi fumarate obtained by the present invention is having an enantiomerically purity of greater than 99.5% and substantially free of diastereomeric impurities.
The above obtained Tenofovir Alafenamide was dissolved in amyl alcohol and methanol and 0.4 moles to 0.6 moles of Fumaric acid was added and stirred for 30 min at room temperature. The above mass was passed through micron filter and washed with methanol. The filtrate mass was distilled out below 3 volumes with respect to batch size under reduced pressure at below 50°C. The reaction mass was heated to 60-65 °C, maintained for 30 min and cooled to room temperature. Cyclohexane was added in to reaction mass and cooled to 0-5°C and maintained for 5 h. The product was isolated by filtration, washed with Cyclohexane and dried the compound at 60-65 °C for 10-12 h under reduced pressure to yield Tenofovir Alafenamide Fumaric acid salt.
In another embodiment of the present invention relates to substantially pure Tenofovir Alafenamide hemi fumarate having enantiomeric purity of greater than 99.5% and total impurities A to J and diastereomeric impurity collectively less than 0.5% by HPLC.
Impurity- A Impurity-B
Impurity-F
Impurity-I
Impurit -J Diastereomeric Impurity The word "Substantially pure" means Tenofovir Alafenamide hemi fumarate having a purity of greater than 99.5 % by HPLC and less than 0.05 % of diastereomeric impurities or the impurity levels within the limits as per the ICH guidelines.
In one embodiment the substantially pure Tenofovir Alafenamide hemi fumarate is having a purity of greater than 99.5 % and meeting the ICH guidelines.
In one embodiment the substantially pure Tenofovir Alafenamide hemi fumarate is having a purity of greater than 99.6 % and meeting the ICH guidelines.
In one embodiment the substantially pure Tenofovir Alafenamide hemi fumarate is having a purity of greater than 99.7 % and meeting the ICH guidelines.
In one embodiment the substantially pure Tenofovir Alafenamide hemi fumarate is having a purity of greater than 99.8 % and meeting the ICH guidelines.
In one embodiment the substantially pure Tenofovir Alafenamide hemi fumarate is having a purity of greater than 99.9 % and meeting the ICH guidelines. The process related impurities that appear in the impurity profile of the Tenofovir
Alafenamide hemi fumarate may be substantially removed by the process of the present invention resulting in the formation of highly pure material. The process of the present invention is as summarized below:
In another embodiment, the Tenofovir Alafenamide or its hemi fumarate obtained by the processes of the present application may be formulated as solid compositions for oral administration in the form of capsules, tablets, pills, powders or granules. In these compositions, the active product is mixed with one or more pharmaceutically acceptable excipients. The drug substance can be formulated as liquid compositions for oral administration including solutions, suspensions, syrups, elixirs and emulsions, containing solvents or vehicles such as water, sorbitol, glycerine, propylene glycol or liquid paraffin.
The compositions for parenteral administration can be suspensions, emulsions or aqueous or non-aqueous sterile solutions. As a solvent or vehicle, propylene glycol, polyethylene glycol, vegetable oils, especially olive oil, and injectable organic esters, e.g.
ethyl oleate, may be employed. These compositions can contain adjuvants, especially wetting, emulsifying and dispersing agents. The sterilization may be carried out in several ways, e.g. using a bacteriological filter, by incorporating sterilizing agents in the composition, by irradiation or by heating. They may be prepared in the form of sterile compositions, which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
Pharmaceutically acceptable excipients used in the compositions comprising Tenofovir Alafenamide hemi fumarate obtained as per the present application process- include, but are but not limited to diluents such as starch, pregelatinized starch, lactose, powdered cellulose, microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, mannitol, sorbitol, sugar and the like; binders such as acacia, guar gum, tragacanth, gelatin, pre-gelatinized starch and the like; disintegrants such as starch, sodium starch glycolate, pregelatinized starch, Croscarmellose sodium, colloidal silicon dioxide and the like; lubricants such as stearic acid, magnesium stearate, zinc stearate and the like; glidants such as colloidal silicon dioxide and the like; solubility or wetting enhancers such as anionic or cationic or neutral surfactants, waxes and the like. Other pharmaceutically acceptable excipients that are of use include but not limited to film formers, plasticizers, colorants, flavoring agents, sweeteners, viscosity enhancers, preservatives, antioxidants and the like.
Pharmaceutically acceptable excipients used in the compositions derived from Tenofovir Alafenamide hemi fumarate of the present application may also comprise to include the pharmaceutically acceptable carrier used for the preparation of solid dispersion, wherever utilized in the desired dosage form preparation.
The following examples illustrate the nature of the invention and are provided for illustrative purposes only and should not be construed to limit the scope of the invention. EXAMPLES
Example 1
Process for the preparation of Phenylhydrogen((R)-l-(6-amino-9H-purin-9-yl)propan- 2-yloxy)methylphosphonate mono hydrate:
Phenol (6.54 g, 0.069 mol), and 1 -methyl 2-pyrrolidinone (NMP) (30.0 mL) was charged in to reaction flask containing anhydrous ((-l-(6-amino-9H-purin-9-yl)propan-2- yloxy)methylphosphonic acid (10.0 g 0.034mol), The reaction mixture was heated to 85°C.
and Triethylamine (TEA) (4.35 g, 0.043 mol) was added slowly. To the obtained reaction mass 1,3-dicyclohexylcarbodiamide (DCC) (1 1.69 g, 0.056 mol) in 1-methyl -2- pyrrolidinone (NMP) (1.1 mL) was added for a period of 6 hours at 100°C. The reaction mixture was stirred for 16 hours and then cooled to 45°C. To the obtained reaction mass, water (20.0 mL) was added slowly, and cooled to 25°C. pHof the reaction mass was adjusted not less than 10 with 25% sodium hydroxide in water. The reaction mass was filtered through the Celite bed and washed with water (3.0 mL). The filtrate was extracted with dichloromethane (20.0 mL) twice. The pH of the aqueous solution was adjusted to 2 to 3 with Conc.HCl. The crude solid was isolated by filtration and washed with methanol (8.7 mL). The wet cake was slurred in methanol (40.0 mL). Solids were isolated by filtration and washed with methanol (6.0 mL). The resulting solid was dried under reduced pressure to yield title compound.
Yield:5.0 g
Chromatographic Purity (By HPLC): 95.05 %
Example 2
Preparation of Racemic Tenofovir Alafenamide:
Thionylchloride (4.09 g, 0.0343 mol ) was charged in to reaction flask containing [(R)-2- (Phenylphosphonomethoxy) propyl] adenine ( 5 g, 0.01376 mol) in Toluene (50 ml) solution. The obtained reaction mass was heated to 75°C to 80°C for 3 hr. The solvent was removed at atmospheric pressure under nitrogen below 80°C, the reaction mixture was washed with (10.0 mL ) of toluene twice at atmospheric pressure under nitrogen below 80°C, cooled to 25°C, diluted with Toluene (15.0 mL) dichloromethane (60.0 mL). In a second reaction flask a mixture of L-alanine isopropyl ester hydrochloride (8.09 g , 0.04815mol) and potassium bicarbonate (5.51 g , 0.0550mol) in dichloromethane (70 ml) was stirred at room temperature for 5 h. Solids formation were observed. The reaction mass was and washed with dichloromethane (10 mL), to remove salts. The filtrate was cooled to -30°C to -10°C. The above obtained acid chloride reaction mass in dichloromethane was added slowly to filtrate mass cooled at -30°C to -10°C (L-alanineisopropyl ester reaction mass in dichloromethane at -30°C to -10°C). The reaction mixture was maintained for lh at same temperature (-30°C to - 10°C). Raised the reaction mass temperature to room temperature. The organic layer was washed with water (25 mL) then aqueous layer and organic layer were separated. The organic layer was washed with 10% sodium di hydrogen orthophosphate solution (2x 25 mL), followed by with 10% potassium bi carbonate solution (25 mL) and water (25 mL). The
organic layer was concentrated and strip off with acetonitrile (2x 10 mL) under reduced pressure below 60°C to give residue compound (Racemic R,S,S:R,R.S=65-80:35-20). Acetonitrile (10.0 mL) was charged in to above residue and heated the reaction mass to 60- 65°C and cooled to 0-5°C for 3 hrs. Filtered the reaction mass and washed with chilled acetonitrile (1.0 mL). The above wet cake was taken into 4 neck RBF Acetonitrile (10.0 mL) was charged in to above wet cake and heated the reaction mass to 60-65°C and cooled to 0- 5°C for 3 hrs. Filtered the reaction mass and washed with chilled acetonitrile (1.0 mL) and dried the compound at50-60°C for 8 h under reduced pressure to yield Tenofovir Alafenamide
Yield: 2.0 g
Chromatographic Purity (By HPLC): 99.70%
Chiral purity by HPLC: 99.80 %
Example 3
Preparation ofcrystalline Tenofovir Alafenamide hemi fumarate Form-STA
To a solution of 9-[(R)-2-[{(S)-[{(S)-l-(isopropoxycarbonyl)ethyl]amino] phenoxy phosphinyl] methoxy] propyl] adenine (5 g , 0.0104 mol) in Amyl alcohol (15.0 mL), Methanol (45.0 mL) charged Fumaric acid (0.609 g) and stirred for 30 min at room temperature . The above mass was passed through micron filter and washed with Methanol (5.0 mL). The filtrate mass was distilled out below 3 volumes with respect to batch size under reduced pressure at below 50°C. The reaction mass was heated to 60-65 °C, maintained for 30 min and cooled to room temperature. Cyclohexane (75.0 mL) was added in to reaction mass and cooled to 0-5 °C and maintained for 5 h. The product was isolated by filtration, washed with Cyclohexane (2.5 mL) and dried the compound at 60-65 °C for 10 h under reduced pressure to yield Tenofovir Alafenamide hemifumarate.
Yield: 5.0 g
Chemical Purity HPLC: 99.88%
Chiral purity by HPLC: 99.97 %
While the foregoing pages provide a detailed description of the preferred embodiments of the invention, it is to be understood that the description and examples are illustrative only of the principles of the invention and not limiting. Furthermore, as many changes can be made to the invention without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.
Claims
Claims:
1) Tenofovir Alafenamide hemifumarate characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 26° peaks selected from 5.2, 7.3, 10.3, 11.1, 18.5, 19.4, 21.1, 22.2, 26.5±0.2°2Θ.
2) Tenofovir Alafenamide hemifumarate according to claim 1 , further characterized by X-ray powder diffraction pattern comprising at 2θ° peaks selected from 10.9, 12.2, 12.8, 14.2, 14.8, 15.3, 15.7, 16.5, 17.6, 18.8, 21.7, 24.4, 26.9 ±0.2°2Θ. 3) Tenofovir Alafenamide hemifumarate according to claim 1, further characterized by DSC isotherm comprising endothermic peak ranging between 109 to 1 14°C.
4) Tenofovir Alafenamide hemifumarate according to claim 1, wherein Tenofovir Alafenamide hemifumarte contain fumaric acid content ranging from 10.4-11.4 % w/w.
5) A process for the preparation of Tenofovir Alafenamide hemifumarate comprising the steps of:
a) dissolving Tenofovir Alafenamide in a solvent;
b) adding fumaric acid;
c) recover the crystalline material; and
d) drying the crystalline material between 60-65°C.
6) A process for the preparation of Tenofovir Alafenamide hemifumarate according to claim- 5, wherein solvent selected from alcohols such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol,amylalcohol; nitrile solvents such as acetonitrile or propionitrile or mixtures thereof.
7) A process for the preparation of Tenofovir Alafenamide (I) according to claim-5; wherein the addition of fumaric acid requires 0.4- 0.6 moles of fumaric acid w.r.t to Tenofovir Alafenamide.
8) A process for the preparation of Tenofovir Alafenamide or its pharmaceutically acceptable salt thereof,comprising the steps of:
comprising the steps of:
a) reacting phenyl hydrogen ((R)-l-(6-amino-9H-purin-9-yl) propan-2-yloxy) methylphosphonate (III) with halogenating agent to provide Phosphonochloridic acid, P-[[(lR)-2-(6-amino-9-H-purin-9-yl)-l-methylethoxy]methyl]-phenyl ester of Formula (IV);
(III) (IV)
b) reacting compound of Formula (IV) with L- Alanine Isopropyl Ester to provide racemic
Tenofovir Alafenamide (V);
c) reacting racemic Tenofovir Alafenamide (V) with a solvent to provide greater than 95% diastereomerically pure Tenofovir Alafenamide (I);
d) optionally treating with acid forming salt to obtain Tenofovir Alafenamide salt. A process for the preparation of Tenofovir Alafenamide according to claim 8, wherein solvent used in step c) is selected from alcohol such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol; ether such as diethyl ether, diisopropyl ether, methyl t-
butyl ether, tetrahydrofuran, 1 ,4-dioxane, 2-methoxyethanol, anisole or nitrile solvents such as acetonitrile or propionitrile or mixtures thereof.
10) A process for the preparation of Tenofovir Alafenamide; wherein Tenofovir Alafenamide or its pharmaceutically acceptable salt thereof is substantially pure having enantiomeric purity of greater than 99.5% and total impurities A to J and diastereomeric impurity collectively less than 0.5% by HPLC.
Impurity-J Diastereomeric Impurity
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641017576 | 2016-05-21 | ||
IN201641017576 | 2016-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017203395A1 true WO2017203395A1 (en) | 2017-11-30 |
Family
ID=60411134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2017/052896 WO2017203395A1 (en) | 2016-05-21 | 2017-05-17 | Crystalline forms of tenofovir alafenamide hemi fumarate |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2017203395A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107522743A (en) * | 2017-09-30 | 2017-12-29 | 深圳科兴生物工程有限公司 | A kind of half fumaric acid tenofovir Chinese mugwort draws phenol amine industrial continuous producing method |
CN108623632A (en) * | 2018-08-17 | 2018-10-09 | 上海麦步医药科技有限公司 | A kind of tenofovir Chinese mugwort draws the preparation method of phenol amine |
WO2019130354A1 (en) | 2017-12-30 | 2019-07-04 | Cipla Limited | Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof |
CN111484527A (en) * | 2019-01-25 | 2020-08-04 | 上海清松制药有限公司 | Preparation method of tenofovir alafenamide intermediate |
CN111943981A (en) * | 2019-05-14 | 2020-11-17 | 博瑞生物医药泰兴市有限公司 | Preparation method of fosaprevir |
CN112782311A (en) * | 2020-12-30 | 2021-05-11 | 南京百泽医药科技有限公司 | HPLC (high performance liquid chromatography) determination method of L-isopropyl alanine in tenofovir disoproxil fumarate |
CN113185552A (en) * | 2021-04-29 | 2021-07-30 | 天地恒一制药股份有限公司 | Preparation method of propane fumarate tenofovir disoproxil degradation impurity |
CN113501846A (en) * | 2021-06-10 | 2021-10-15 | 江苏豪森药业集团有限公司 | Almenopterine tenofovir hemifumarate compound, crystal form, preparation method and application thereof |
CN113549111A (en) * | 2020-04-24 | 2021-10-26 | 北京康派森医药科技有限公司 | Preparation method of tenofovir alafenamide fumarate impurity |
CN114671915A (en) * | 2021-12-31 | 2022-06-28 | 浙江车头制药股份有限公司 | Preparation method of high diastereoisomer phosphonyl chloride |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013025788A1 (en) * | 2011-08-16 | 2013-02-21 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
WO2014195724A1 (en) * | 2013-06-07 | 2014-12-11 | Cipla Limited | An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl] methoxy]propyl]adenine |
-
2017
- 2017-05-17 WO PCT/IB2017/052896 patent/WO2017203395A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013025788A1 (en) * | 2011-08-16 | 2013-02-21 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
WO2014195724A1 (en) * | 2013-06-07 | 2014-12-11 | Cipla Limited | An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl] methoxy]propyl]adenine |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107522743A (en) * | 2017-09-30 | 2017-12-29 | 深圳科兴生物工程有限公司 | A kind of half fumaric acid tenofovir Chinese mugwort draws phenol amine industrial continuous producing method |
WO2019130354A1 (en) | 2017-12-30 | 2019-07-04 | Cipla Limited | Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof |
CN108623632A (en) * | 2018-08-17 | 2018-10-09 | 上海麦步医药科技有限公司 | A kind of tenofovir Chinese mugwort draws the preparation method of phenol amine |
CN111484527A (en) * | 2019-01-25 | 2020-08-04 | 上海清松制药有限公司 | Preparation method of tenofovir alafenamide intermediate |
CN111943981A (en) * | 2019-05-14 | 2020-11-17 | 博瑞生物医药泰兴市有限公司 | Preparation method of fosaprevir |
CN113549111A (en) * | 2020-04-24 | 2021-10-26 | 北京康派森医药科技有限公司 | Preparation method of tenofovir alafenamide fumarate impurity |
CN112782311A (en) * | 2020-12-30 | 2021-05-11 | 南京百泽医药科技有限公司 | HPLC (high performance liquid chromatography) determination method of L-isopropyl alanine in tenofovir disoproxil fumarate |
CN113185552A (en) * | 2021-04-29 | 2021-07-30 | 天地恒一制药股份有限公司 | Preparation method of propane fumarate tenofovir disoproxil degradation impurity |
CN113501846A (en) * | 2021-06-10 | 2021-10-15 | 江苏豪森药业集团有限公司 | Almenopterine tenofovir hemifumarate compound, crystal form, preparation method and application thereof |
CN114671915A (en) * | 2021-12-31 | 2022-06-28 | 浙江车头制药股份有限公司 | Preparation method of high diastereoisomer phosphonyl chloride |
CN114671915B (en) * | 2021-12-31 | 2024-04-09 | 浙江车头制药股份有限公司 | Preparation method of high diastereoisomer phosphonochloride |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017203395A1 (en) | Crystalline forms of tenofovir alafenamide hemi fumarate | |
EP3077404B1 (en) | Purification of tenofovir alafenamide and its intermediates | |
US8759515B2 (en) | Process for the preparation of tenofovir disoproxil fumarate | |
CA2707790C (en) | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
US20110312977A1 (en) | Process for the preparation of voriconazole | |
US8962832B2 (en) | Process for the preparation of ambrisentan and novel intermediates thereof | |
AU2013340559A1 (en) | Antiviral phosphonate analogues and process for preparation thereof | |
EP2755959A1 (en) | Rilpivirine hydrochloride | |
WO2011025932A2 (en) | Preparation of sitagliptin and salts thereof | |
WO2010026603A2 (en) | Novel amine salts of tenofovir, process for producing the same and use thereof in production of tenofovir dioproxil | |
US20170218006A1 (en) | Synthesis of Phosphoramidates | |
US9518020B2 (en) | Process for Regorafenib | |
KR102476361B1 (en) | New polycrystalline form of tenofovir prodrug, and preparation method and application therefor | |
WO2017191565A1 (en) | Process for preparation of macitentan | |
US11111250B2 (en) | Polymorphs of Ribociclib mono succinate | |
WO2013132314A1 (en) | Tenofovir phosphate, processes for the preparation and pharmaceutical composition thereof | |
WO2016042576A1 (en) | Co-crystal of sofosbuvir and amino acid and process for preparation thereof | |
US20180162896A1 (en) | Synthesis of Phosphoramidates | |
CN108341841B (en) | Salt of tenofovir alafenamide and aspartic acid | |
WO2021165995A1 (en) | Novel salts and/or co-crystals of tenofovir alafenamide | |
US20090111998A1 (en) | Process for the preparation of carvedilol dihydrogen phosphate hemihydrate and pharmaceutical compositions thereof | |
US9381199B2 (en) | Linagliptin solid dispersion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17802280 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17802280 Country of ref document: EP Kind code of ref document: A1 |